This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Neurocrine Biosciences Inc. (NBIX)
Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia Call
March 27, 2012 08:00 am ET
Kevin Gorman - President & CEO
Jane Sorenson - IR
Chris O'Brien - CMO
Thomas Wei - Jefferies
Robyn Karnauskas - Deutsche Bank
Phil Nadeau - Cowen & Company
Jon LeCroy - MKM
Joshua Schimmer - Leerink Swann
Good day everyone and welcome to this Neurocrine announces Phase II Results of the VMAT2 Inhibitor call. At this time all sites are on a listen-only mode (Operator Instructions). As a reminder today's call may be recorded and it's now my pleasure to introduce our first speaker, President and CEO, Mr. Kevin Gorman. Please go ahead sir.
Thank you very much and thank everyone for joining us this morning. I'm joined here with Chris O'Brien, our Chief Medical Officer and Tim Coughlin, our CFO. Before we get started, I would like Jane Sorenson to read our Safe Harbor statement please.
Good morning. I want to remind you of Neurocrine’s Safe Harbor precautions. Certain statements made in the course of this conference call that state the company's or management's intentions, hopes, believes, expectations or predictions of the future are forward-looking statements which are subject to risks and uncertainties. Information concerning factors that could cause the actual results to differ materially from those contained in or implied by the forward-looking statements is contained in the company's SEC filings, including but not limited to the company's annual report on Form 10-K and quarterly reports on Form 10-Q.